Skip to main content

Day: August 2, 2021

Abcam to Acquire BioVision for $340 million

Written by Customer Service on . Posted in Mergers And Acquisitions.

CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) — Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) (“Abcam”, “the Company” or “the Group”), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. (“BioVision”), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). Transaction highlightsBioVision is a fast-growing innovator and distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell-based assay kits Brings one of Abcam’s large third-party suppliers in-house Accelerates Abcam’s strategic execution and focus on in-house innovation and products in the complementary biochemical...

Continue reading

Heineken Holding N.V. reports 2021 half year results

Written by Customer Service on . Posted in Public Companies.

Amsterdam, 2 August 2021 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) announces: KEY HIGHLIGHTSThe net result of Heineken Holding N.V.’s participating interest in Heineken N.V. for the first half year of 2021 amounts to €517 million Net revenue (beia) €9,971 million, +14.1% organic growth Net revenue (beia) organic growth per hectolitre +5.5% Consolidated beer volume organic growth +9.6% Heineken® volume +19.6% Operating profit (beia) organic growth +109.3% Net profit (beia) €896 million, +320.3% organic growth EverGreen strategy deployment at HEINEKEN has started Full year expectations unchanged: financial results to remain below 2019. FINANCIAL SUMMARY1IFRS Measures € million Total growth   BEIA Measures € million Organic growth2Revenue 11,970    7.3  %  ...

Continue reading

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Written by Customer Service on . Posted in Public Companies.

Geneva, Switzerland, August 2, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021. Tim Dyer, CEO, Roger Mills, CMO and Robert Lütjens, Head of Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 ET / 07:00 PT) the same day. Title:                Addex Half-Year 2021 Financial ResultsDate:               August 5, 2021Time:               16:00 CEST (15:00 BST / 10:00 ET / 07:00 PT) Joining the Conference Call:1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in...

Continue reading

Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kalinichev as Head of Translational Science

Written by Customer Service on . Posted in Public Companies.

Geneva, Switzerland, August 2, 2021 (GLOBE NEWSWIRE) – Ad Hoc Announcement Pursuant to Art. 53 LR Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced the appointment of Mikhail Kalinichev, PhD, as Head of Translational Science. Dr. Kalinichev is a seasoned pharmaceutical R&D professional with more than 20 years of diversified experience at leading pharmaceutical companies and academic institutions in France, Denmark, Switzerland, UK and USA. “It’s great to have Mikhail back on the Addex team! He is an accomplished neuropharma researcher and drug developer who already knows Addex and our research programs,” said Tim Dyer, CEO of Addex. “We look forward to his contribution to our pipeline as we advance multiple...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.